I kliniske undersøgelser med Helixate NexGen indtraf dette hos 14% af tidligere ubehandlede patienter og hos 17% af de børn, der tidligere var blevet behandlet i under fem dage.
In clinical trials with Helixate NexGen, this happened in 14% of previously untreated patients and in 17% of children who had been treated for less than five days in the past.